EUVIMEDEUVIMED entdecken
Crossref

Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy

Daisuke Hirokawa, Moyoko Tomiyasu, Masaki Sonoda iD, Jun Suenaga, Hiroaki Goto, Noriko Aida, Tetsuya Yamamoto

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31957 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Daisuke Hirokawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Methotrexate, Leukoencephalopathies, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Kanagawa Prefectural Hospital Pediatric Medical Fund for 2020 and 2021, and KAKENHI, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methotrexate (MTX)‐induced leukoencephalopathy is a significant neurological complication in pediatric acute lymphoblastic leukemia (ALL) treatment. Magnetic resonance spectroscopy (MRS) is a noninvasive method to assess metabolic changes associated with neurotoxicity. This study aimed to evaluate the diagnostic and prognostic value of MRS‐derived metabolite levels, particularly N ‐acetylaspartate and N ‐acetylaspartylglutamate (tNAA), in MTX‐induced leukoencephalopathy. Procedure We retrospectively analyzed 89 pediatric patients with ALL who underwent brain magnetic resonance imaging (MRI) and MRS at Kanagawa Children's Medical Center between 2009 and 2022. A total of 261 MRS datasets were examined, focusing on metabolic changes in the centrum semiovale. Using mixed logistic regression, we evaluated the association between tNAA levels and leukoencephalopathy onset, as well as their correlation with clinical recovery after MTX discontinuation.

Results

Patients with leukoencephalopathy had significantly lower tNAA levels than those of controls. A predictive model indicated that a 1.0‐point decrease in pretreatment tNAA levels was associated with an approximately 3.22‐fold increase in the odds of developing MTX‐induced leukoencephalopathy. Furthermore, increasing tNAA levels over time were significantly correlated with clinical improvement.

Conclusion

This study suggests that tNAA levels measured using MRS may serve as a potential biomarker for diagnosing and monitoring MTX‐induced leukoencephalopathy. Integrating MRS into clinical assessments may represent a promising future approach to facilitate earlier intervention, inform treatment strategies, and potentially improve patient outcomes, pending validation by future prospective studies. These findings highlight the importance of MRS in the real‐time evaluation of disease progression and therapeutic responses in pediatric patients undergoing MTX treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateLeukoencephalopathiesPrecursor Cell Lymphoblastic Leukemia-LymphomaAntimetabolites, AntineoplasticAspartic AcidHumansMaleFemaleChildRetrospective StudiesChild, PreschoolMagnetic Resonance SpectroscopyAdolescentInfantPrognosisFollow-Up StudiesMagnetic Resonance ImagingBiomarkers

Stichwörter der Autor:innen

magnetic resonance spectroscopymetabolite biomarkersmethotrexate‐induced leukoencephalopathypediatric neurotoxicitywhite matter injury

Substanzen

MethotrexateAntimetabolites, AntineoplasticAspartic AcidN-acetylaspartateBiomarkers

Autor:innen und Institutionen

  • Department of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Department of Radiology, Kanagawa Children's Medical Center, Yokohama, Japan.
  • Department of Molecular Imaging and Theranostics, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan.
  • Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Hematology/Oncology, Department of Pediatrics, Kanagawa Children's Medical Center, Yokohama, Japan.

ORCID-Profile: Masaki Sonoda

Förderung

  • Kanagawa Prefectural Hospital Pediatric Medical Fund for 2020 and 2021
  • and KAKENHI
  • Japan Society for the Promotion of Science

Zitieren

APA

Hirokawa, D., Tomiyasu, M., Sonoda, M., Suenaga, J., Goto, H., Aida, N., & Yamamoto, T. (2025). Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31957

Vancouver

Hirokawa D, Tomiyasu M, Sonoda M, Suenaga J, Goto H, Aida N, et al. Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31957

BibTeX
@article{Hirokawa2025,
  author = {Hirokawa, Daisuke and Tomiyasu, Moyoko and Sonoda, Masaki and Suenaga, Jun and Goto, Hiroaki and Aida, Noriko and Yamamoto, Tetsuya},
  title = {Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31957}
}
Kostenlos starten →